BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1
86 results:

  • 1. Identification of prognostic stemness-related genes in kidney renal papillary cell carcinoma.
    Liu Y; Yao Y; Zhang Y; Xu C; Yang T; Qu M; Lu B; Song X; Pan X; Zhou W; Cui X
    BMC Med Genomics; 2024 May; 17(1):121. PubMed ID: 38702698
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Integrative epigenome-transcriptome analysis unravels cancer-specific over-expressed genes potentially regulating immune microenvironment in clear cell renal cell carcinoma.
    Gadewal N; Natu A; Sen S; Rauniyar S; Bastikar V; Gupta S
    Biochim Biophys Acta Gen Subj; 2024 May; 1868(5):130596. PubMed ID: 38471632
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.
    Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
    JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Association between Dietary Inflammatory Potential and Urologic Cancers: A Meta-analysis.
    Dai YN; Yi-Wen Yu E; Zeegers MP; Wesselius A
    Adv Nutr; 2024 Jan; 15(1):100124. PubMed ID: 37940476
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Mobile Phone Use and Risks of Overall and 25 Site-Specific Cancers: A Prospective Study from the UK Biobank Study.
    Zhang Y; Zhang Y; Ye Z; Yang S; Liu M; Wu Q; Zhou C; He P; Gan X; Qin X
    Cancer Epidemiol Biomarkers Prev; 2024 Jan; 33(1):88-95. PubMed ID: 37870426
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. runx1 predicts poor prognosis and correlates with tumor progression in clear cell renal carcinoma.
    Ma J; He S; Li M; Peng Y; Yang X; Chen L; Jia Q; Liu Y
    Pathol Res Pract; 2023 Nov; 251():154886. PubMed ID: 37844486
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
    Cunningham L; Merguerian M; Calvo KR; Davis J; Deuitch NT; Dulau-Florea A; Patel N; Yu K; Sacco K; Bhattacharya S; Passi M; Ozkaya N; De Leon S; Chong S; Craft K; Diemer J; Bresciani E; O'Brien K; Andrews EJ; Park N; Hathaway L; Cowen EW; Heller T; Ryan K; Barochia A; Nghiem K; Niemela J; Rosenzweig S; Young DJ; Frischmeyer-Guerrerio PA; Braylan R; Liu PP
    Blood; 2023 Dec; 142(25):2146-2158. PubMed ID: 37738626
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. MTAN: A semi-supervised learning model for kidney tumor segmentation.
    Sun P; Yang S; Guan H; Mo T; Yu B; Chen Z
    J Xray Sci Technol; 2023; 31(6):1295-1313. PubMed ID: 37718833
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.
    Saal J; Bald T; Eckstein M; Ralser DJ; Ritter M; Brossart P; Grünwald V; Hölzel M; Ellinger J; Klümper N
    JAMA Oncol; 2023 Aug; 9(8):1048-1055. PubMed ID: 37347489
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. MR texture analysis in the differentiation of renal oncocytoma with localized renal cell carcinoma subtypes.
    Wang Y; Zhang X; Wang S; Chen Y
    Br J Radiol; 2023 Aug; 96(1148):20221009. PubMed ID: 37129341
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Genetic proxies for calcium channel blockers and cancer: a Mendelian randomization study.
    Fan B; Schooling CM; Zhao JV
    J Hum Hypertens; 2023 Nov; 37(11):1028-1032. PubMed ID: 37117874
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Life-threatening hemoptysis in patients with metastatic kidney cancer.
    Patel VM; Elias R; Asokan A; Sharma A; Christie A; Pedrosa I; Chiu H; Reznik S; Hannan R; Timmerman R; Brugarolas J
    Clin Genitourin Cancer; 2023 Aug; 21(4):497-506. PubMed ID: 37045713
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
    Wu K; Liu X; Wang Y; Wang X; Li X
    Front Public Health; 2022; 10():994351. PubMed ID: 36388369
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Elevated systemic immune inflammation level increases the risk of total and cause-specific mortality among patients with chronic kidney disease: a large multi-center longitudinal study.
    Lai W; Xie Y; Zhao X; Xu X; Yu S; Lu H; Huang H; Li Q; Xu JY; Liu J; Chen S; Liu Y
    Inflamm Res; 2023 Jan; 72(1):149-158. PubMed ID: 36352033
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Identification of Novel Genes and Associated Drugs in Advanced Clear Cell Renal Cell Carcinoma by Bioinformatic Methods.
    Lu M; Xiao L; Xu B; Gao Q
    Tohoku J Exp Med; 2022 Aug; 258(2):79-90. PubMed ID: 35896362
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
    Bedke J; Rini BI; Plimack ER; Stus V; Gafanov R; Waddell T; Nosov D; Pouliot F; Soulières D; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Tamada S; Nguyen AM; Wan S; Perini RF; Rhoda Molife L; Atkins MB; Powles T
    Eur Urol; 2022 Oct; 82(4):427-439. PubMed ID: 35843776
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Young age is associated with decreased recurrence for renal cell carcinoma.
    Liu F; Davaro F; Wong R; Siddiqui S; Hamilton Z
    Can J Urol; 2022 Jun; 29(3):11142-11149. PubMed ID: 35691035
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. MCPIP1 regulates focal adhesion kinase and Rho GTPase-dependent migration in clear cell renal cell carcinoma.
    Gorka J; Marona P; Kwapisz O; Rys J; Jura J; Miekus K
    Eur J Pharmacol; 2022 May; 922():174804. PubMed ID: 35257717
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.
    Bommareddy K; Hamade H; Lopez-Olivo MA; Wehner M; Tosh T; Barbieri JS
    JAMA Dermatol; 2022 Mar; 158(3):275-282. PubMed ID: 35138351
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment.
    Wallach JD; Deng Y; McCoy RG; Dhruva SS; Herrin J; Berkowitz A; Polley EC; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Shah ND; Ross JS; Lyon TD
    JAMA Netw Open; 2021 Oct; 4(10):e2130587. PubMed ID: 34677594
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.